Astellas and IBL to develop recombinant human protein made using transgenic silkworms
Possibility of producing new medicines using this technology
Japanese pharmaceutical firm Astellas is to collaborate with Immuno-Biological Laboratories to develop pharmaceutical applications of recombinant human proteins made using transgenic silkworms.
The firms will examine and evaluate the production method and possibly develop new medicines.
IBL has developed a production system for the efficient secretion of soluble recombinant proteins in the cocoon of transgenic silkworms and has succeeded in the production of various useful proteins including antibodies and human collagen. The firm is actively progressing with the commercialisation of these proteins as raw materials for reagents in research, in vitro diagnostics, cosmetics and veterinary drugs.